Pfizer weighs job cuts in Korea; CEO Soriot beefs up AZ stake with £3M share purchase; Sanofi eyes expansion in England;

@FiercePharma: China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: ICYMI: AstraZeneca sales team revving up for new Brilinta marketing push. More | Follow @CarlyHFierce

> Pfizer ($PFE) is eyeing its operations in South Korea for job cuts, with plans to offer early retirement to a range of employees in the region. Report

> AstraZeneca ($AZN) CEO Pascal Soriot has plowed an additional £3 million of his money into AstraZeneca stock, adding more than 76,000 shares to his holdings. Report

> Sanofi ($SNY) has filed for permission to expand its production facilities in Cheshire, England, with additional manufacturing, warehouse and lab space. Report

> Sanofi's Prague-based generics unit Zentiva produces more than half the company's generics products, delivering drugs to countries in Europe, Asia, Africa and the Middle East. Report

Medical Device News

@FierceMedDev: Updated w/ company comment: Merck, Daktari collaborating on hep C diagnostic. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: HeartWare looks diversify into mitral valve repair with $929M purchase of Valtech Cardio. Article | Follow @VarunSaxena2

@EmilyWFierce: European pharma lobby says 'non' to French funding for off-label Avastin. ICYMI fron FiercePharma | Follow @EmilyWFierce

> Stratasys launches 3-D printer for production of dental devices. Story

> Valeant to buy microsurgery tools company Synergetics for up to $190M. Article

Biotech News

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Looking forward to an upcoming panel discussion on organ-on-a-chip tech. And you can't beat the price. More | Follow @JohnCFierce

@DamianFierce: Look at this idiot thing I wrote last year. Article | Follow @DamianFierce

> Booming Gilead gets a blueprint for a big new HQ addition. Report

> Regeneron's genetics team IDs a candidate for ultra-rare bone disease. Story

> Celyad set to scale up China-focused R&D activities after linking with Medisun. More

> Acadia finally delivers long-delayed application for 'breakthrough' Parkinson's drug. Article

Vaccines News

> Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan. More

> Cornell grad looks to change the way parents remember vaccine schedules. Report

> GlaxoSmithKline signs on LimmaTech for vaccine R&D. Story

> NHS meningitis B vaccination scheme begins in U.K. Item

> BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII. Article

CRO News

> PPD partners up to better track trial events. News

> WuXi looks to Japan for manufacturing growth. Report

> BioClinica opens an app umbrella to unite researchers. More

> Chinese drugmaker trades $200M for CDMO Cytovance. Story

> AMRI signs on to help Saneca develop opium-based drugs. Article

Pharma Manufacturing News

> Sun gets direct line to poppy production with buyout of GSK opiates biz. Report

> Lannett manufacturing capacity balloons to 522,000 sq. ft. in short order. Story

> China poaches Indian scientists to build formulation expertise. News

> Novo building huge warehouse to support production expansion. Item

> Sun recalls yet another med made at troubled Halol plant. Report

Pharma Asia News

> Pharma market bets on ASEAN in focus ahead of economic pact. Story

> HK's Medisun, Belgium's Celyad revise C-Cure pact for Greater China. Item

> China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. Report

> GSK hep B supplies to Japan hit by Tianjin explosion. Story

> Abbott touts Japan drug-eluting Absorb stent trial results, but no approval timeline. Article

And Finally... Scientists dug into a range of biologic meds for rheumatoid arthritis to find that there was a higher risk of infections in Medicare patients who'd switched to Enbrel (etanercept) from another biologic compared with Orencia (abatacept). Report